Research project led by Bailey Hanna, MS, RDN - no affiliate links, ads or sponsored products.
A single prospective, double-blind, placebo-controlled trial assessed the effects of Lactobacillus reuteri ATCC 55730 on 39 adults with IBS-D, IBS-C, or IBS-M.(1) Unfortunately, the study’s quality was inadequate, leading to its exclusion from our database.
Key data such as means, standard deviations, and specific symptom outcomes for both the probiotic and placebo groups were missing, with only combined group data provided.
While the study indicated a potential reduction in constipation and flatulence for the probiotic group, these results weren’t statistically significant compared to the placebo. The lack of detailed data prevented us from calculating effect sizes for these symptoms independently. Additionally, there were high attrition rates in both the probiotic and placebo groups (22.2% and 33.3%, respectively).
Key Takeaway
This study was excluded from our database due to significant data gaps. Based on the available evidence, we cannot recommend Lactobacillus reuteri ATCC 55730 for managing IBS.
Recommended Dosing
None
Reference:
There is insufficient evidence demonstrating benefits for IBS with this probiotic. Therefore, we do not provide guidance on finding a commercial product containing this strain/blend.
This probiotic has low quality studies in IBS populations supporting it. View our evidence evaluation framework to learn how we assess the quality of studies.
Add condition
The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome–a double blind, placebo-controlled, randomized study
Clin Nutr Dec
ADULTS 19-70 years
No data
There were no statistically significant differences found between the groups for constipation. However, the results indicated a possible improvement, with a lowered frequency of constipation observed (p=0.0714).
There were no significant improvements observed in the Francis Severity Score for global IBS symptoms.
There were no statistically significant differences between the groups for “passing gases.” However, there was an indication of a possible improvement, with a lowered frequency of passing gases observed (p=0.0971).
The changes in the severity score and the various components of the total Quality of Life (QOL) score were analyzed for both the entire study population and the specific study and placebo groups. While the entire study population showed significant improvements over time in all study parameters, no significant differences were found between the study and placebo groups.